Matthew & Stephen, part 2
Founders, BlueGreen Clinical
Key Points
- Governance in clinical trials is about oversight and management
- Building trust and transparency with CROs is essential
- Vendor selection should be a thorough and well-planned process
- Offboarding and closeouts are critical to trial success
- Technology can enhance vendor management but should not replace relationships
- Risk management should be integrated from the start of the trial process
- Metrics should be meaningful and not just for the sake of data collection
The conversation continues with complexities of governance, vendor management, and risk management in clinical trials. Matt and Steve discuss the importance of understanding governance as it relates to oversight and management, the critical elements of vendor selection and off-boarding, and the necessity of building strong relationships with CROs. They emphasise the importance of a proactive approach to risk management. The discussion highlights the need for clear communication, documentation, and a balanced approach to ensure successful trial outcomes.
Chapters
About the Guest
Matthew Hersch & Stephen Crow
Founders, BlueGreen Clinical
With 20 years in Clinical Operations at a pioneering cannabinoid biotech, Matthew Hersch and Stephen Crow guided its growth from startup to mid-sized pharma. Their hands-on experience spans trial management, CRO oversight, team building, and GCP inspections.
In 2023, they founded BlueGreen Clinical to help biotechs build strong Clinical Operations foundations, sharing hard-won insights from their journey.
Want to discuss vendor oversight?
Book a consultation with Tom Lazenby to explore how Mayet can support your clinical QA needs.